Navigation Links
Regeneron Reports Fourth Quarter and Full Year 2012 Financial and Operating Results
Date:2/14/2013

utive Officer of Regeneron.  "With the recent U.S. approval of EYLEA for the treatment of macular edema following central retinal vein occlusion (CRVO), and receipt of a Medicare J-Code for EYLEA in January 2013, we expect continued strong U.S. growth for EYLEA and forecast U.S. net sales of $1.2 billion to $1.3 billion in 2013.  Outside the U.S., our partner Bayer HealthCare has begun to launch EYLEA for the treatment of neovascular age-related macular degeneration (wet AMD) in Japan, Europe, Australia, and other regions, and we expect to see substantial sales growth through 2013 and beyond as pricing approvals are received." 

"Clinical development of EYLEA in additional indications continued to progress in 2012, as the Phase 3 program in diabetic macular edema (DME) was fully enrolled and a Phase 3 trial in macular edema following branch retinal vein occlusion (BRVO) was initiated," said George D. Yancopoulos, M.D., Ph.D., Chief Scientific Officer, and President, Regeneron Laboratories.  "Our pipeline also advanced significantly during 2012, with the roll-out of our broad Phase 3 ODYSSEY program for REGN727, an antibody targeting PCSK9 to reduce low-density lipoprotein (LDL) cholesterol, and the full enrollment of our first Phase 3 trial for sarilumab, our IL-6 receptor antibody in rheumatoid arthritis.  We are also encouraged by the potential of our IL-4R inhibitor, REGN668.  REGN668 demonstrated positive proof of concept in allergic asthma and atopic dermatitis, and data from these trials will be submitted to medical conferences for presentation later in the year.  We look forward to starting later stage, Phase 2b trials with this antibody during 2013."

Business Highlights - Fourth Quarter 2012 and 2013 to Date EYLEA® (aflibercept) Injection for Intravitreal Injection

  • The Company and Bayer HealthCare collaborate on the global development and commercialization of EYLEA outside the U
    '/>"/>

  • SOURCE Regeneron Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. Regeneron Announces Receipt of Hart-Scott-Rodino Notice
    2. Regeneron to Report Fourth Quarter and Full Year 2012 Financial and Operating Results and Host Conference Call and Webcast on February 14, 2013
    3. Regeneron Announces Presentation at the Deutsche Bank 2012 dbAccess BioFEST
    4. Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
    5. Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
    6. BioMed Realty Announces 80,500 Square Foot Lease Expansion For Regeneron Pharmaceuticals
    7. Regeneron Named Worlds #1 Biopharmaceutical Employer in Science Magazine Annual Survey
    8. Regeneron Announces September 2012 Investor Conference Presentations
    9. Regeneron to Report Second Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on July 25, 2012
    10. Regeneron Announces June 2012 Investor Conference Presentations
    11. Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/22/2014)... Sept. 22, 2014 Paragon 28, ... commercial launch of its foot plating system that supplants ... The GORILLA TM R3CON PLATING SYSTEM greatly enhances ... TM & Mini-Monster TM Screw Systems and ... of 10 interchangeable subsystems, the GORILLA TM R3CON ...
    (Date:9/22/2014)... 2014 Research and Markets  has announced ... 2014-2018" report to their offering. ... comprehensive and up-to-date publication available covering the neurotechnology industry. ... markets, competitors, and growth rates in four key segments ... 2018. It forecasts the number of systems to be ...
    (Date:9/22/2014)... , Sept. 22, 2014  Elusys Therapeutics, Inc. ... treat infectious disease, today announced it has completed ... of obiltoxaximab (ETI-204). Obiltoxaximab is an anti-toxin in ... data from these studies support the safety and ... at the intended therapeutic dose. The conclusion of ...
    Breaking Medicine Technology:Paragon 28, Inc. Launches the GORILLA(TM) R3CON PLATING SYSTEM 2The Market for Neurotechnology: 2014-2018 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 5Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 6
    ... 20 Muscadine grape skin powder, from ... /), provided significant protection against radiation damage in an ... reported in April of 2009 at the 100th Annual ... Denver, Colorado.(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/CL01715 )The ...
    ... prototype 3D display exceeds performance expectations.LIVONIA, Mich., April 20 ... Heritage Hospital surgeons and their medical support team assembled to ... test the new LifeVision(TM) family of 3D technologies developed by ... event marks the first time in history that ...
    Cached Medicine Technology:Muscadine Grape Skin Dietary Supplement Protects against Cancer Therapy Radiation Side Effects 2Oakwood Surgeons Perform World's First 3D Surgery Without Special Glasses 2Oakwood Surgeons Perform World's First 3D Surgery Without Special Glasses 3Oakwood Surgeons Perform World's First 3D Surgery Without Special Glasses 4
    (Date:9/23/2014)... Village, CA (PRWEB) September 23, 2014 ... Dental Office is now offering complimentary oral sedation with ... 15 percent of Americans suffer from dental anxiety or ... uncomfortable for patients; they can also keep patients from ... anxiety or phobia in Westlake Village and surrounding areas ...
    (Date:9/23/2014)... YORK, NY (PRWEB) September 23, 2014 ... best innovators in the pharmaceutical industry with their annual ... bestowed at a gala banquet at Gotham Hall in ... and brand managers representing top talent and brands. ... celebrate its accomplishments,” says Anna Stashower, CEO and Publisher ...
    (Date:9/23/2014)... Gurnee, IL (PRWEB) September 23, 2014 ... lighting solutions, has expanded its MedMaster™ M4 product ... The luminaire extends the M4 product line – ... green LED options – providing more flexibility when ... of the MedMaster M4 Series include:, ...
    (Date:9/23/2014)... 2014 The U.S. Pharmacopeial Convention (USP) ... Health Organization (WHO) regarding the assignment of Biological Qualifiers ... by the Expert Group of the Programme of International ... to the naming of all biologicals that is consistent ... assessment of these drugs. , Hence, USP supports ...
    (Date:9/23/2014)... N.J. (PRWEB) September 23, 2014 ... provider of advanced delivery technologies and development ... products, today announced that it had reached ... privately held biopharmaceutical company, Cingulate Therapeutics (CTx), ... of new prescription pharmaceutical products for the ...
    Breaking Medicine News(10 mins):Health News:The Sedation Dental Office is Now Offering Complimentary Oral Sedation with Treatment for New Patients 2Health News:The Sedation Dental Office is Now Offering Complimentary Oral Sedation with Treatment for New Patients 3Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 2Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 3Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 4Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 5Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 6Health News:Kenall Expands MedMaster™ M4 Surgical Suite Product Portfolio with New 1'×4' Option 2Health News:Kenall Expands MedMaster™ M4 Surgical Suite Product Portfolio with New 1'×4' Option 3Health News:USP Comments to WHO Regarding Biologics Qualifier Proposal 2Health News:Catalent and Cingulate Therapeutics Sign Exclusive Agreement for Development of New ADHD Treatments 2Health News:Catalent and Cingulate Therapeutics Sign Exclusive Agreement for Development of New ADHD Treatments 3
    ... , TUESDAY, March 22 (HealthDay News) -- The death ... and were in remission two years after treatment was similar ... study shows. Italian researchers collected data on 832 patients ... and found that 20 patients died during the follow-up period. ...
    ... HealthDay Reporter , TUESDAY, March 22 (HealthDay News) -- ... on the rise in the United States despite research that ... say. Fibrates are often prescribed to people with low ... triglycerides, a harmful form of fat circulating in the blood, ...
    ... , TUESDAY, March 22 (HealthDay News) -- A low-cost ... of 400 seemingly healthy children and teens in a pilot ... screen all school-aged children for heart conditions that can lead ... Children,s Hospital of Philadelphia said in a hospital news release. ...
    ... , TUESDAY, March 22 (HealthDay News) -- Depression can worsen ... South Korean researchers used X-rays to assess the severity ... and older. The patients were also evaluated for the severity ... of pain were higher in patients whose X-rays showed greater ...
    ... and welfare reforms, and their use of ,nudge, theory, hark ... of the nineteenth century, according to studies by a University ... in the Lancet . Dr Kim Price,s article ... his second in the Lancet within a year drawing parallels ...
    ... researchers find when women explore their feelings about being or ... humorous. Findings from the project entitled ,Look at me! Images ... feelings about images of ageing. These findings are presented in ... April. Ageing is undoubtedly about the body, and pressure ...
    Cached Medicine News:Health News:Leukemia Patients Taking Gleevec Achieve 'Normal' Death Rate 2Health News:Study Questions Rise in Use of Certain Cholesterol Drugs 2Health News:Study Questions Rise in Use of Certain Cholesterol Drugs 3Health News:Study Questions Rise in Use of Certain Cholesterol Drugs 4Health News:Screening Seems to Catch Dangerous Heart Condition in Kids 2Health News:Depression May Boost Arthritis Pain 2Health News:Report indicates that 'new' welfare reforms hark back to Victorians 2Health News:Look at me! 2Health News:Look at me! 3Health News:Look at me! 4
    Ribbon malleable, general purpose retractor....
    The Wire Cutters are designed to cut Kirschner wires up to 2.5 mm diameter easily and smoothly. They are particularly useful for external fixation applications. The Wire Cutters shear fixation wires ...
    The osteotome shafts are manufactured with stainless steel and are available both straight and curved in 1/4" and 1/2" sizes....
    ... Pulse CDC Compact Cardiac Digital Camera is a ... open, patient-friendly gantry, and provides full sized fields ... into your clinic you need a flexible system ... Find out how the Pulse reduces the ...
    Medicine Products: